Company* (Symbol) | Product | Description | Indication | Status (Date) |
CANCER |
||||
Bioniche Life Sciences Inc. (Canada; TSE:BNC) | ND | Mycobacterial cell wall complex composition technology | Prostate cancer | Company was granted regulatory approval to begin studies of the technology in Canada (1/17) |
Cel-Sci Corp. (AMEX:CVM) | Multikine | Immunotherapy drug; natural mixture of human cytokines, including interleukin-2 | Head and neck cancer | Company gained permission to start a Phase II trial in Mexico (1/4) |
NaPro BioTherapeutics Inc. (NPRO) | Biotax | Version of paclitaxel | Cancer | Company received marketing approval in Israel (1/9) |
Oxford Biomedica plc* (UK) | TroVax | Cancer vaccine; targeted at tumor-associated antigens | Colorectal cancer | Medicines Control Agency approved the initiation of a Phase I/II trial (1/2) |
PhotoCure ASA (Norway) | Metvix | Topical photodynamic therapy | Basal cell carcinoma | Phase III results showed 90% of all skin cancer lesions were cured within three months (1/10**) |
Phytopharm plc (UK; LSE:PYM) | P54 | An extract of the spice turmeric, formulated with volatile oils; a nonsteroidal anti-inflammatory that works by inhibiting the production of the pro-inflammatory enzyme cyclo-oxygenase 2 | Colorectal cancer | Phase I results showed P54 was safe and well tolerated (1/10**) |
Theratechnologies Inc. (Canada; TSE:TH) | Theralux | Ex vivo photodynamic cell therapy system | Non-Hodgkin's lymphoma | The first patient was enrolled at Maisonneuve-Rosemont Hospital in a pivotal clinical trial (1/29) |
DIABETES |
||||
ReNeuron Holdings plc (UK) | ReN1869 | Small-molecule compound, a member of the neurin family | Diabetic neuropathy and inflammatory arthritis | Company filed for approval to begin a Phase II trial (1/3**) |
INFECTION |
||||
BioChem Pharma Inc. (Canada; BCHE) and GlaxoSmith-Kline plc (UK) | Trizivir | Triple drug combining abacavir sulphate, lamivudine and zidovudine | HIV | Trizivir received marketing approval in Europe (1/4) |
BioMarin Pharmaceuticals Inc. (BMRN) | rhASB | Recombinant human arylsufatase B; enzyme replacement therapy | Mucopolysaccharidosis VI | Committee for Orphan Medical Products in Europe gave a positive opinion on company's aplication for orphan designation (1/4) |
Cangene Corp. (Canada; TSE:CNJ) | VariZIG | Antibody against the Varicella zoster virus that causes chicken pox | Chicken pox | Company received marketing approval in Canada (1/22) |
MISCELLANEOUS |
||||
Alizyme plc (UK; LSE:AZM) | ATL-962 | Lipase inhibitor that prevents the breakdown of fat in the gut | Obesity | Phase Ib results provided evidence of efficacy and showed the lipase inhibitor to be safe and well tolerated (1/10**) |
Bio-Technology General Corp. (BTGC) | Zomacton | Recombinant human growth hormone | Turner's syndrome | The Ferring Group, Bio-Technology's European licensee, received European regulatory approval (1/8) |
Cerus Corp. (CERS) and Baxter Healthcare Corp. (NYSE:BAX) | Intercept Platelet System | A system to inactivate bacteria, viruses and other pathogens and white blood cells in platelets intended for transfusion | Pathogen inactivation in platelets intended for transfusion | Companies submitted a CE Mark application for European marketing approval (1/2) |
Dyax Corp. (DYAX) and Debiopharm SA (Switzerland) | EPI-HNE-4 | Human neutrophil elastase inhibitor | Cystic fibrosis | Debiopharm completed a Phase Ib trial in Europe, finding the compound to be well tolerated and safe (1/25) |
Galen Holdings plc (Northern Ireland; GALN) | ND | Intravaginal ring-based product | Hormone replacement therapy | Company received an approvable letter in the UK to market the product (1/23) |
Pharmos Corp. (PARS) | Dexanabinol | Anti-oxidant, anti-inflammatory compound and an N-methyl-D-aspartate antagonist | Traumatic brain injury | Company initiated a pivotal Phase III study in Europe (1/10) |
Phytopharm plc (UK; LSE:PYM) | P45 | Cream; topical formulation of plant extract | Male pattern baldness (alopecia androgenica) | Phase II results showed a 40% placebo effect (1/24**) |
Theratechnologies Inc. (Canada; TSE:TH) | ThGRF 1-44 peptide | Growth hormone-releasing factor analogue | Sleep disorders and hip fractures | Company filed two IND applications in Canada to begin a 2nd Phase II trial in sleep disorders and a Phase I trial in hip fractures (1/9) |